A collaborative effort for a common goal
The VOLABIOS project is powered by a multidisciplinary consortium of 18 partners and 2 affiliated organizations from 11 European countries. These partners bring together a wealth of expertise from academia, clinical research, technology, public health, and policymaking, ensuring a comprehensive and innovative approach to advancing schizophrenia diagnosis and monitoring.
Project Partners
Our consortium includes:
Academic and Research Institutions
Leading universities and research centers
conducting groundbreaking studies on mental health and diagnostics.
Clinical Centers
Hospitals and healthcare organizations at the forefront of patient
care and clinical trials.
Technology Developers
Experts in artificial intelligence, mobile spectrometry, and
data analysis driving innovation.
Public Health Organizations
Policymakers and health authorities aligning the project
with public health priorities.
How Our Collaboration Works
The success of VOLABIOS relies on close collaboration among its partners, each contributing their unique strengths:
- Data Sharing: Collaborative use of multi-omics data and clinical insights.
- Interdisciplinary Research: Integration of expertise across various scientific fields.
- Strategic Guidance: Input from an advisory board of internationally recognized experts in psychiatry, neuroscience, and public health.
Why collaboration matters
The scale and complexity of schizophrenia diagnosis require a global effort. By uniting diverse perspectives and expertise, VOLABIOS ensures:
- Rigorous scientific standards.
- Sustainable and impactful solutions for mental health diagnostics.
- Broad applicability of its findings across healthcare systems.